Acelyrin (NASDAQ:SLRN) Receives New Coverage from Analysts at Wells Fargo & Company
Wells Fargo & Company initiated coverage on shares of Acelyrin (NASDAQ:SLRN – Free Report) in a research report sent to investors on Wednesday morning, MarketBeat.com reports. The brokerage issued an equal weight rating and a $11.00 price objective on the stock. A number of other analysts also recently commented on the stock. Citigroup assumed coverage […]